Advertisement

A New Concept of Breast Cancer Growth Regulation and its Potential Clinical Applications

  • C. Kent Osborne
Part of the Reproductive Biology book series (RBIO)

Abstract

Major changes in our conceptual thinking about the regulation of growth of human breast cancer have occurred in the past decade. In the early 1970s our understanding of the mechanisms regulating breast cancer cell proliferation was simplistic. The pituitary hormone prolactin was thought to be important due to its critical involvement in normal breast differentiation and function and because it has a pivotal role in rodent breast cancer (Welsch and Nagasawa, 1977). However, the importance of this hormone in human breast cancer remains to be defined. The female sex steroid hormone estrogen, on the other hand, was known to be an important growth factor since the observation that about one-third of patients with breast cancer would have temporary tumor regression following treatments designed either to lower the serum estrogen level or to block its effects. Later estrogens and antiestrogens also were reported to have direct effects on proliferation of cultured human breast cancer cells (Lippman et al., 1977). At this time cumulative data suggested that the mechanisms of estrogen action on cells involved the binding of estrogen to the estrogen receptor protein followed by the tight coupling of the receptor-hormone complex to DNA resulting in alterations of specific gene transcription and protein synthesis. Exactly how estrogens increased cell proliferation was not known. Nevertheless, knowledge of these simple biochemical pathways had important clinical implications that eventually led to the use of estrogen receptor assays for predicting response to endocrine therapy and for predicting the clinical course of patients with early stage disease.

Keywords

Breast Cancer Breast Cancer Cell Breast Cancer Cell Line Human Breast Cancer Cell Human Breast Cancer Cell Line 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Arteaga C.L., Coronado E., and Osborne C.K. 1988a. Blockade of the epidermal growth factor receptor inhibits transforming growth factor a-induced but not estrogen-induced growth of hormone-dependent human breast cancer. Mol. Endocrinol. (in press).Google Scholar
  2. Arteaga C.L., Hanauske A.-R., Clark C.M., Osborne C.K., Hazarika P., Pardue R.L., and Von Hoff D.D. 1988b. Immunoreactive α transforming growth factor (IraTGF) activity in effusions from cancer patients: A marker of tumor burden and patient prognosis. Cancer Research. (in press).Google Scholar
  3. Arteaga C.L., Kitten L., Coronado E., Jacobs S., Kuli F., and Osborne C.K. 1988c. Blockade of the type I somatomedin receptor inhibits growth of estrogen receptor negative human breast cancer cells in athymic mice. Proc. 70th Annual Meeting Endocrine Society 191:683 (Abstract).Google Scholar
  4. Arteaga C.L., Tandon A.K., Von Hoff D.D., and Osborne C.K. 1988d. Transforming growth factor β: Potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells. Cancer Research 48:3898.PubMedGoogle Scholar
  5. Clemmons D.R., Elgin R.C., Han V.K.M., Casella S.V., D’Ercole A.J., and Van Wyk J.J. 1986. Cultured fibroblast monolayers secrete a protein that alters the cellular binding of somatomedin-C/insulin like growth factor I. J. Clin. Invest. 77:1548.PubMedCrossRefGoogle Scholar
  6. Coronado E., Ramasharma K., Li C.H., Kitten L., Marshall M., Fuqua S., and Osborne K. 1988. Insulin-like growth factor II (IGF-II): A potential autocrine growth factor for human breast cancer. Proc. Am. Assoc. Cancer Res. 29:237 (Abstract).Google Scholar
  7. Cuttitta F., Carney D.N. Mulshine J., Moody T.W., Fedorko J., Fischler A., and Minna J.D. 1985. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature (London) 309: 823.CrossRefGoogle Scholar
  8. Furlanetto R.W. and DiCarlo J.N. 1984. Somatomedin-C receptors and growth effects in human breast cells maintained in long-term tissue culture. Cancer Research 44:2122.PubMedGoogle Scholar
  9. Hanauske A.R., Arteaga C.L., Clark C.M., Buchok J., Marshall M., Hazarika P., Pardue R.L., and Von Hoff D.D. 1988. Determination of transforming growth factor activity in effusions from cancer patients. Cancer (Phil.) 61:1832.CrossRefGoogle Scholar
  10. Huff K.K., Knabbe C., Lindsey R., Kaufman D., Bronzert D., Lippman M.E., and Dickson R.B. 1988. Multihormonal regulation of insulin-like growth factor-I-related protein in MCF-7 human breast cancer cells. Mol. Endocrinol. 2:200.PubMedCrossRefGoogle Scholar
  11. Ikeda T., Danielpour D., and Sirbasku B.A. 1983. Isolation and properties of endocrine and autocrine type mammary tumor cell growth factors (estromedins), In: “Progress in Cancer Research and Therapy”, Vol. 31 (F. Bresciani et al., eds.) Raven Press. New York. p.144.Google Scholar
  12. Karey K.P. and Sirbasku D.A. 1988. Differential responsiveness of human breast cancer cell lines MCF-7 and T47D to growth factors and 17-β-estradiol. Cancer Research 48:4083.PubMedGoogle Scholar
  13. Knabbe C., Lippman M.E., Wakefield L.M., Flanders K.C., Kasid A., Derynck R., and Dickson R.B. 1987. Evidence that transforming growth factor-β is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48:417.PubMedCrossRefGoogle Scholar
  14. Lippman M.E., Dickson R.B., Bates S., Knabbe C., Huff K., Swain S., McManaway M., Bronzert D., Kasid A., and Gelmann E.P. 1986. Autocrine and paracrine growth regulation of human breast cancer. Breast Cancer Res. Treat. 7:59.PubMedCrossRefGoogle Scholar
  15. Lippman M., Monaco M.E., and Bolan G. 1977. Effects of estrone, estradiol, and estriol on hormone-responsive human breast cancer in long-term tissue culture. Cancer Research 37:1901.PubMedGoogle Scholar
  16. Massague J. 1987. The TGF-β family of growth and differentiation factors. Cell 49:437.PubMedCrossRefGoogle Scholar
  17. Masui H., Kawamoto T., Sato J.D., Wolf B., Sato G., and Mendelsohn J. 1984. Growth inhibition of human tumor cells in athymic mice by antiepidermal growth factor receptor monoclonal antibodies. Cancer Research 44:1002.PubMedGoogle Scholar
  18. Nunez A.-M., Jakowlev S., Briand J.-P., Gaire M., Krust A., Rio M.-C., and Chambon P. 1987 Characterization of the estrogen-induced pS2 protein secreted by the human breast cancer cell line MCF-7. Endocrinology 121:1759.PubMedCrossRefGoogle Scholar
  19. Osborne C.K., Bolan G., Monaco M.E., and Lippman M.E. 1976. Hormone responsive human breast cancer in long term tissue culture: Effect of insulin. Proc. Natl. Acad. Sci. (USA) 73:4536.CrossRefGoogle Scholar
  20. Osborne C.K., Hamilton B., and Nover M. 1982. Receptor binding and processing of epidermal growth factor by human breast cancer cells. J. Clin. Endocrinol. Metab. 55:86.CrossRefGoogle Scholar
  21. Osborne C.K., Hamilton B., Titus G., and Livingston R.B. 1980. Epidermal growth factor stimulation of human breast cancer cells in tissue culture. Cancer Research 40:2361.PubMedGoogle Scholar
  22. Osborne C.K., Monaco M.E., Lippman M.E., and Kahn C.R. 1978. Correlation among insulin binding, degradation, and biological activity in human breast cancer cells in long-term tissue culture. Cancer Research 38:94.PubMedGoogle Scholar
  23. Osborne C.K., Ross C.R., Coronado B.S., Fuqua S.A.W., and Kitten, L. J. 1988. Secreted growth factors from estrogen receptor-negative human breast cancer do not support growth of estrogen receptor-positive breast cancer in the nude mouse model. Breast Cancer Res. Treat. 11:211.PubMedCrossRefGoogle Scholar
  24. Peokonen F., Partanen S., Makinen T., and Rutanen E.-M. 1988. Receptors for epidermal growth factor and insulin-like growth factor I and their relation to steroid receptors in human breast cancer. Cancer Research 48:1343.Google Scholar
  25. Peres R., Betsholtz C., Westermark B., and Heldin C.-H. 1987. Frequent expression of growth factors for mesenchymal cells in human mammary carcinoma cell lines. Cancer Research 47:3425.PubMedGoogle Scholar
  26. Picard O., Rolland Y., and Poupon M.F. 1986. Fibroblast-dependent tumor-igenieity of cells in nude mice: Implication for implantation of metastases. Cancer Research 46:3290.PubMedGoogle Scholar
  27. Rochefort H., Capony F., Garcia M., Vacailles V., Freiss G., Chambon M., Morisset M., and Vignon F. 1987. Estrogen-induced lysosomal proteases secreted by breast cancer cells: a role in carcinogenesis? J. Cell Biochem. 35:17.PubMedCrossRefGoogle Scholar
  28. Salomon D.S., Zwiebel J.A., Bano M., Losonczy I., Fehnel P., and Kidwell W.R. 1984. Presence of transforming growth factors in human breast cancer cells. Cancer Research 44:4069.PubMedGoogle Scholar
  29. Sporn M.B., Roberts A.B., Wakefield L.M., and Assoian R.K. 1986. Transforming growth factor-β: Biological function and chemical structure. Science 233:532.PubMedCrossRefGoogle Scholar
  30. Tucker R. F., Volkenaut M.E., Branum E.L., and Moses E.L. 1983. Comparison of intra-and extracellular transforming growth factors from nontransformed and chemically transformed mouse embryo cells. Cancer Research 43:1581.PubMedGoogle Scholar
  31. Welsch C.W. and Nagasawa H. 1977. Prolactin and murine mammary tumorigenesis: A review. Cancer Research 37:951.PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1989

Authors and Affiliations

  • C. Kent Osborne
    • 1
  1. 1.Department of Medicine/OncologyUniversity of Texas Health Science CenterSan AntonioUSA

Personalised recommendations